Señales en vivo de TARS | Maximiza tus Ganancias con Getagraph.com

VENDER 116844 min ago

@ $29.83

Emitido: 13 feb 2024 @ 11:42

Retorno: 23.53%

Señal anterior: feb 9 - 09:30

Señal anterior: Comprar

Retorno: -3.38 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions...

Stats
Volumen de hoy	652 217
Volumen promedio	697 548
Capitalización de mercado	1.38B
EPS	$0 ( 2024-02-27 )
Próxima fecha de ganancias	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.98
ATR14	$0.0780 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Mottiwala Aziz	Buy	12 938	Common Stock
2024-03-18	Mottiwala Aziz	Sell	4 766	Common Stock
2024-03-15	Mottiwala Aziz	Sell	8 148	Restricted Stock Units
2024-03-15	Mottiwala Aziz	Sell	4 790	Restricted Stock Units
2024-03-15	Wahl Bryan	Buy	12 038	Common Stock

INSIDER POWER
31.24
Last 100 transactions
Buy: 1 038 524 \| Sell: 656 594

Volumen Correlación

Largo: 0.33 (neutral)

Corto: -0.65 (weak negative)

Signal:(63.364) Neutral

Tarsus Pharmaceuticals, Correlación

10 Correlaciones Más Positivas
NVCN	0.951
AGNCP	0.949
SILK	0.943
VCEL	0.941
ADTH	0.94
TIOAU	0.936
ROVR	0.935
TIOA	0.935
BRIVU	0.931
INBK	0.93

10 Correlaciones Más Negativas
CRCT	-0.945
SGML	-0.943
VRM	-0.942
OSTK	-0.94
TBLT	-0.94
IRBT	-0.939
MYMD	-0.939
SNAX	-0.939
REVB	-0.936
TENX	-0.931

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tarsus Pharmaceuticals, Correlación - Moneda/Commodity

-0.79
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

-0.74
( moderate negative )

-0.51
( weak negative )

0.19
( neutral )

Tarsus Pharmaceuticals, Finanzas

Annual	2023
Ingresos:	$17.45M
Beneficio Bruto:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2023
Ingresos:	$17.45M
Beneficio Bruto:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2022
Ingresos:	$25.82M
Beneficio Bruto:	$24.86M (96.30 %)
EPS:	$-2.52

FY	2021
Ingresos:	$57.03M
Beneficio Bruto:	$57.03M (100.00 %)
EPS:	$-0.00200

Financial Reports:

No articles found.

Tarsus Pharmaceuticals,

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Actualizaciones en tiempo real para Tarsus Pharmaceuticals, [TARS]

Upcoming Earnings Alert